Fig. 6
Systemically administered allogeneic MSCs do not increase tumor malignancy. At dysplasia stage, hamsters received intracardially vehicle or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. At end of study period (13 weeks), tumors were assessed microscopically. Stage frequency was calculated for each group. Bar = 100 μm (number of replicates = 6, n = 14). MSC mesenchymal stem cell